J&J Pharma Presents Robust Pipeline And Outlines New R&D Structure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In a wide-ranging presentation to Wall Street, the company highlights key new products in development and an R&D strategy built around five therapeutic areas